Repare Therapeutics Gestione
Gestione criteri di controllo 2/4
Repare Therapeutics Il CEO è Lloyd Segal, nominato in Sep2016, e ha un mandato di 8.17 anni. la retribuzione annua totale è $ 4.99M, composta da 12.3% di stipendio e 87.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.28% delle azioni della società, per un valore di $ 331.21K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.5 anni e 4.7 anni.
Informazioni chiave
Lloyd Segal
Amministratore delegato
US$5.0m
Compenso totale
| Percentuale dello stipendio del CEO | 12.3% |
| Mandato del CEO | 8.2yrs |
| Proprietà del CEO | 0.3% |
| Durata media del management | 5.5yrs |
| Durata media del Consiglio di amministrazione | 4.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher
Nov 13
There's No Escaping Repare Therapeutics Inc.'s (NASDAQ:RPTX) Muted Revenues Despite A 35% Share Price Rise
Oct 05Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data
Aug 30Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?
Jul 12Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues
May 01Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet
Mar 12We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
Feb 15Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth
Dec 20Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Oct 24New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)
Aug 14Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week
May 14Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results
May 12Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough
May 08Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%
Mar 03Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Oct 27Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Sep 07Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M
Aug 04Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go
Jun 27Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Jun 24Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans
Mar 02We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn
Oct 14We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Apr 16Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?
Mar 12Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$84m |
| Jun 30 2024 | n/a | n/a | -US$69m |
| Mar 31 2024 | n/a | n/a | -US$46m |
| Dec 31 2023 | US$5m | US$615k | -US$94m |
| Sep 30 2023 | n/a | n/a | -US$97m |
| Jun 30 2023 | n/a | n/a | -US$3m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$4m | US$592k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$26m |
| Jun 30 2022 | n/a | n/a | -US$132m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$4m | US$572k | -US$107m |
| Sep 30 2021 | n/a | n/a | -US$94m |
| Jun 30 2021 | n/a | n/a | -US$77m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$5m | US$505k | -US$53m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$2m | US$430k | -US$27m |
Compensazione vs Mercato: La retribuzione totale di Lloyd ($USD 4.99M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 649.07K ).
Compensazione vs guadagni: La retribuzione di Lloyd è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Lloyd Segal (60 yo)
8.2yrs
Mandato
US$4,991,804
Compensazione
Mr. Lloyd Mitchell Segal serves as Director at HotKnot Therapeutics, Inc. Mr. Segal has been the Chief Executive Officer, President and Director of Repare Therapeutics Inc. since September 2016. Mr. Segal...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 8.2yrs | US$4.99m | 0.28% $ 331.2k | |
| Executive VP & CFO | 5.1yrs | US$1.93m | 0.034% $ 40.5k | |
| Executive VP & Chief Medical Officer | 5.5yrs | US$2.09m | 0.47% $ 561.4k | |
| Co-Founder | no data | Nessun dato | Nessun dato | |
| Co-Founder | no data | Nessun dato | Nessun dato | |
| Co-Founder | no data | Nessun dato | Nessun dato | |
| Executive VP & Chief Scientific Officer | 5.5yrs | US$1.83m | 0.098% $ 116.7k | |
| Executive Vice President of Human Resource | 1.5yrs | Nessun dato | 0.0037% $ 4.4k | |
| Executive Vice President of Discovery | 8.4yrs | Nessun dato | 0.055% $ 65.8k | |
| Executive VP | 2.8yrs | Nessun dato | 0.0092% $ 11.0k |
5.5yrs
Durata media
53yo
Età media
Gestione esperta: Il team dirigenziale di RPTX è esperto e expertise (durata media dell'incarico 5.5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 8.2yrs | US$4.99m | 0.28% $ 331.2k | |
| Independent Director | 4.4yrs | US$274.74k | 0.0094% $ 11.2k | |
| Independent Director | 5.2yrs | US$265.41k | 0% $ 0 | |
| Independent Director | 1.4yrs | US$664.86k | 0% $ 0 | |
| Independent Director | less than a year | Nessun dato | Nessun dato | |
| Independent Director | 5yrs | US$265.31k | 0% $ 0 | |
| Independent Chairman | 3.2yrs | US$291.49k | 0.018% $ 21.1k | |
| Independent Director | 5.7yrs | US$272.99k | 0.019% $ 22.5k |
4.7yrs
Durata media
58yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di RPTX sono considerati esperti (durata media dell'incarico 4.7 anni).